Abo Bibliothek: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Erscheint 6 Ausgaben pro Jahr

ISSN Druckformat: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Options and Opportunities for Clinical Management and Treatment of Psoriasis

Volumen 30, Ausgabe 1, 2013, pp. 51-90
DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005589
Get accessGet access

ABSTRAKT

Psoriasis is a complex, multifactorial disease that appears to be influenced by immune-mediated components. For many years the pathogenesis of psoriasis has been discordant; the clinical picture suggested that the psoriasis was secondary to abnormal keratinocyte proliferation and differentiation, but later the role of the T cell was revealed. A variety of treatment options range from topical agents (e.g., coal tar, dithranol, and emollients for milder forms) to systemic agents (i.e., methotrexate or cyclosporin), and phototherapy. Recently, biologics have been added to this list that target particular steps in the immune or inflammatory pathways. Various nanocarriers (e.g., liposomes, niosomes, and microemulsions) have been successfully exploited for the delivery of several antipsoriatic drugs. This review provides insight into various psoriasis treatment strategies−from conventional to novel−currently in use or in development as well as the novel targets that have been explored and/or investigated for anti-psoriatic therapy. The pathogenesis of psoriasis and some of the topical, systemic biological, and novel approaches currently in use or in development are reviewed here. The pros and cons of each treatment strategy are presented, as are some of the animal models used to study features reminiscent of psoriasis. This information can be used to better the understanding of treatment options for this disease.

REFERENZIERT VON
  1. Marianecci Carlotta, Di Marzio Luisa, Rinaldi Federica, Celia Christian, Paolino Donatella, Alhaique Franco, Esposito Sara, Carafa Maria, Niosomes from 80s to present: The state of the art, Advances in Colloid and Interface Science, 205, 2014. Crossref

  2. Liu Qing, Wu Ding-Hong, Han Ling, Deng Jing-Wen, Zhou Li, He Rui, Lu Chuan-Jian, Mi Qing-Sheng, Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers, Experimental Dermatology, 26, 4, 2017. Crossref

  3. Börjesson Clothilde, Guinard Elisabeth, Tauber Marie, Konstantinou Maria-Polina, Livideanu Cristina B., Mazereeuw-Hautier Juliette, Meyer Nicolas, Paul Carle, Compounded topical preparations in plaque psoriasis: Still a place for it in 2018?, Dermatologic Therapy, 32, 1, 2019. Crossref

  4. Vishkaei Mansoureh Nazari, Ahamed Mohamed B. Khadeer, Majid Amin Malik Shah Abdul, Development of Ethosome Formulation for Topical Therapeutic Applications, in Novel Drug Delivery Systems for Phytoconstituents, 2019. Crossref

  5. Geifman N., Azadbakht N., Zeng J., Wilkinson T., Dand N., Buchan I., Stocken D., Di Meglio P., Warren R.B., Barker J.N., Reynolds N.J., Barnes M.R., Smith C.H., Griffiths C.E.M., Peek N., Defining trajectories of response in patients with psoriasis treated with biologic therapies, British Journal of Dermatology, 185, 4, 2021. Crossref

  6. Guinea-Viniegra Juan, Jiménez María, Schonthaler Helia B., Navarro Raquel, Delgado Yolanda, José Concha-Garzón María, Tschachler Erwin, Obad Susanna, Daudén Esteban, Wagner Erwin F., Targeting miR-21 to Treat Psoriasis , Science Translational Medicine, 6, 225, 2014. Crossref

  7. Chen Lin, Li Jie, Yao Ying, Wang Shanlong, Zheng Shuangjin, Ju Xinggang, Zhang Bin, Circulating microRNA profile unveils mechanisms of action of acitretin for psoriasis vulgaris, Bioengineered, 12, 1, 2021. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain